Dose escalation study of cal

Dose Escalation Study of CAL-101 in Select Relapsed or ...

★ ★ ☆ ☆ ☆

7/4/2008 · A Phase 1, sequential dose escalation followed by cohort expansion study of CAL-101, an oral inhibitor of PI3K delta, in patients with relapsed or refractory CLL, select B-cell NHL and AML.

Dose Escalation Study of CAL-101 in Select Relapsed or ...

Phase 1 Trial Design: Is 3 + 3 the Best? - Home | Moffitt

★ ★ ★ ★ ★

Dose-Escalation Designs Phase 1 trials must prioritize safety while attempting to maintain efficiency. A typical dose-escalation phase 1 study selects a safe starting dose based on preclini-cal data from in vitro and in vivo testing of the drug. Incremental dose increases for assigned patient cohorts

Phase 1 Trial Design: Is 3 + 3 the Best? - Home | Moffitt

A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in ...

★ ★ ★ ★ ★

A Phase I/IIa Dose Escalation Safety Study of [REDACTED] in Patients with Cervical Sensorimotor Complete Spinal Cord Injury Public Abstract: The proposed project is designed to assess the safety and preliminary activity of escalating doses of human embryonic stem cell derived oligodendrocyte progenitor cells (OPCs) for the treatment of spinal ...

A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in ...

Dose Escalation and Dose Expansion Study of Tirabrutinib ...

★ ★ ☆ ☆ ☆

5/29/2015 · Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Dose Escalation and Dose Expansion Study of Tirabrutinib ...

Phase 1, Open‐Label, Dose Escalation, Safety, and ...

★ ★ ★ ★ ☆

BACKGROUND: The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmaco- kinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors.

Phase 1, Open‐Label, Dose Escalation, Safety, and ...

Tamoxifen in advanced prostatic carcinoma. A dose ...

★ ★ ★ ☆ ☆

Tamoxifen in Advanced Prostatic Carcinoma A Dose Escalation Study FRANK M. TORTI, MD,'-t***§vIIBERT L. LUM, PHARMD,t'§ RICHARD LO, MI3,S.n FUAD FREIHA, MD.t*T AND LINDA SHORTLIFFE, MD,t*§(I Patients with advanced prostatic carcinoma who had received minimal or no prior therapy were treated with tamoxifen citrate in escalating doses from 10 to 50 mg orally twice a day.

Tamoxifen in advanced prostatic carcinoma. A dose ...

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor ...

★ ★ ★ ★ ☆

The main limitations of this study are that it was a non-randomised, single-arm, dose-escalation study, with a relatively small number of patients within each disease type, which limits the generalisability of the results and the ability to compare data from this study to studies of other PI3Kδ inhibitors.

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor ...

Dose Escalated, Hypofractionated Radiotherapy Using ...

★ ★ ★ ★ ★

Dose Escalation Study www.tcrt.org To improve local control for inoperable non-small cell lung cancer (NSCLC), a phase I dose escalation study for locally advanced and medically inoperable patients was devised to es-calate tumor dose while limiting the dose to organs at risk including the esophagus, spinal cord, and residual lung.

Dose Escalated, Hypofractionated Radiotherapy Using ...

A phase 1, open-label, dose escalation study of ...

★ ★ ★ ☆ ☆

METHODS: The authors undertook a phase 1 study of gemcitabine in combination with escalating doses of paricalcitol administered weekly intravenously in patients with advanced cancers. A standard 3+3 dose escalation schema was used. Pharmacokinetic assessment of gemcitabine and its metabolite 2’,2’-difluorodeoxyuridine (dFdU) was performed.

A phase 1, open-label, dose escalation study of ...

Intellikine commences INK1117 Phase I dose escalation ...

★ ★ ★ ☆ ☆

10/12/2011 · The Phase I study of INK1117 will consist of a dose escalation phase in patients with advanced solid malignancies, followed by expansion cohorts in …

Intellikine commences INK1117 Phase I dose escalation ...

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor ...

★ ★ ★ ★ ★

this first-in-human phase 1 study was to establish the safety and preliminary activity profile of umbralisib in patients with haematological malignancies. Methods We did an open-label, phase 1, dose-escalation study at seven clinics in the USA. We recruited patients aged at

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor ...

(PDF) A Dose-Escalation Study to Evaluate the Safety ...

★ ★ ☆ ☆ ☆

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open ...

(PDF) A Dose-Escalation Study to Evaluate the Safety ...

Hyperfractionated conformal radiotherapy in locally ...

★ ★ ★ ★ ★

hormones and 28 patients did. However, at the 78-Gy In this report, we present interim results on a study de- dose level, only 8 of 25 patients received hormones com- signed to test the feasibility of dose escalation using hy- pared with 20 of 24 at the 82.8-Gy dose level.

Hyperfractionated conformal radiotherapy in locally ...

A Phase I dose escalation and expansion clinical trial of ...

★ ★ ★ ☆ ☆

A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors

A Phase I dose escalation and expansion clinical trial of ...

(PDF) First-in-human, open-label dose-escalation and dose ...

★ ★ ★ ★ ★

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

(PDF) First-in-human, open-label dose-escalation and dose ...

A phase 1 clinical trial evaluating marizomib ...

★ ★ ★ ★ ★

study enrolment. Study design This was an international, multicentre, Phase 1, open label, dose-finding study that had a primary endpoint of determin-ing the maximum tolerated dose (MTD) and/or recom-mended Phase 2 dose (RP2D) of patients with RRMM. The secondary endpoints were to …

A phase 1 clinical trial evaluating marizomib ...

Should the Rate of Opioid Dose Escalation Be Included as a ...

★ ★ ★ ★ ☆

The use of opioid dose escalation as a clini-cal marker has historically evolved over time. Opioid dose escalation was initially included as a prognostic feature in the original Edmon-ton Staging System (ESS) for pain classifica-tion in advanced cancer patients.4 In a pilot study of the ESS, Bruera et al. designated

Should the Rate of Opioid Dose Escalation Be Included as a ...

Research Studies - Allergy & Asthma Associates of Southern ...

★ ★ ★ ☆ ☆

Research Studies Our research center is dedicated to the research, development and progress of new therapies for a number of different disorders that will improve the quality of life for patients. We are continually enrolling patients of all ages in research studies. ... A Dose Escalation Study of AF-219 in Refractory Chronic Cough. A ...

Research Studies - Allergy & Asthma Associates of Southern ...

Phase I, Dose-Escalation Study of the Targeted Cytotoxic ...

★ ★ ★ ★ ★

Background: AEZS-108, formerly AN-152, is a cytotoxic hybrid molecule consisting of an LHRH agonist moiety covalently coupled to doxorubicin, allowing it to deliver doxorubicin selectively to cells expressing LHRH receptors. LHRH receptors are expressed on the cell membrane of many tumors, including prostate cancer (PC). This Phase I study determined the maximum tolerated dose (MTD) of AEZS ...

Phase I, Dose-Escalation Study of the Targeted Cytotoxic ...

Cytrx initiates tamibarotene and TRISENOX combination dose ...

★ ★ ★ ★ ☆

9/14/2009 · CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with ...

Cytrx initiates tamibarotene and TRISENOX combination dose ...

Niraparib Maintenance Therapy in Platinum-Sensitive ...

★ ★ ★ ★ ☆

dose-escalation study, which showed that the maximum dose of 300 mg per day resulted in an ... cal Trial groups and investigators in the United States, Canada, and Hungary, our objective was ...

Niraparib Maintenance Therapy in Platinum-Sensitive ...

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A ...

★ ★ ★ ★ ☆

Study Design Subjects could be enrolled in this phase 2 dose-escalation study if they were judged clinically likely to benefit from daxibotulinum-toxinA at a low dose (cohort 1), a medium dose (cohort 2), or a high dose (cohort 3). Enrollment in cohorts 2 and 3 could only proceed after 6-week safety data from the preceding cohort had

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A ...

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K ...

★ ★ ★ ★ ★

7/1/2017 · Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Dejan Juric, Ian Krop, Ramesh K. Ramanathan, Timothy R. Wilson, ... Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K ...

Phase I, Dose-Escalation Study of the Targeted Cytotoxic ...

★ ★ ☆ ☆ ☆

12/15/2014 · Because the experience with AEZS-108 was limited to female patients, we designed a dose-escalation study of AEZS-108 in men with CRPC before launching a phase II trial (NCT01240629). The primary objective of this phase I study was to determine the MTD of AEZS-108 given intravenously every 21 days in men with CRPC.

Phase I, Dose-Escalation Study of the Targeted Cytotoxic ...

Clinical Track - Demystifying Medicine

★ ★ ★ ★ ☆

Methods and Results: A phase 1b, open-label, single-dose escalation study was conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501). Four cohorts with stable CHD and low HDL-C were dosed (0.9, 3.0, 9.0, and 13.5 mg/kg, single 1-hour infusions) and followed up for 28 days.

Clinical Track - Demystifying Medicine

Risks and Benefits of Phase 1 Clinical Trial Participation

★ ★ ★ ★ ★

Risks and Benefits of Phase 1 Clinical Trial Participation Amit Mahipal, MD, and Danny Nguyen, MD ... the decision of whether to escalate the dose of the study drug quickly (such that patients develop toxici - ties sooner) or whether to escalate the dose slowly ... demonstrated that …

Risks and Benefits of Phase 1 Clinical Trial Participation
Study-of-the-meaning-life.html,Study-of-the-tempcore-process.html,Study-of-unidentified.html,Study-of-wimax.html,Study-on-dysmenorrhea.html